Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)
Subscribe To Our Newsletter & Stay Updated
